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Abstract: Perturbation of mitochondrial function and subsequent induction of cell death 
pathways are key hallmarks in neonatal hypoxic-ischemic (HI) injury, both in animal models 
and in term infants. Mitoprotective therapies therefore offer a new avenue for intervention 
for the babies who suffer life-long disabilities as a result of birth asphyxia. Here we show 
that after oxygen-glucose deprivation in primary neurons or in a mouse model of HI, 
mitochondrial protein homeostasis is altered, manifesting as a change in mitochondrial 
morphology and functional impairment. Furthermore we find that the mitochondrial fusion 
and cristae regulatory protein, OPA1, is aberrantly cleaved to shorter forms. OPA1 cleavage 
is normally regulated by a balanced action of the proteases Yme1L and Oma1. However, in 
primary neurons or after HI in vivo, protein expression of YmelL is also reduced, whereas 
no change is observed in Oma1 expression. Our data strongly suggest that alterations in 
mitochondria-shaping proteins are an early event in the pathogenesis of neonatal HI injury. 
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1. Introduction 
Moderate to severe hypoxic-ischemic encephalopathy (HIE), caused by a lack of oxygen or blood 
flow to the brain around the time of birth, affects 1.5 in every 1000 live births in the UK and far more in 
the developing world [1–3]. The consequences for babies and parents affected by HIE are devastating; 
15%–20% of infants will die in the postnatal period and a further 25% will develop severe and  
long-lasting neurological impairments [4]. 
In infants and in animal models of hypoxic-ischemic injury (HI) there is an initial depletion of ATP, 
phosphocreatine and glucose within the brain followed by a transient recovery to almost physiological 
levels [5]. However, a second, rapid energy failure facilitates the majority of cell death [6–8]. We and 
others have shown that HI triggers multiple signaling events such as NMDA/AMPA receptor activation, 
release of reactive oxygen species and increase in intracellular calcium [9–12]. In addition, cell death 
after neonatal brain injury is characterized morphologically by a mixed necrotic–necroptotic–apoptotic 
phenotype depending on time post injury and brain region [10,13,14]. However, data from our lab and 
others strongly suggest that the common thread linking these diverse mechanisms is mitochondrial 
dysfunction [15,16]. 
It is well established that in animal models of neonatal HI, mitochondrial respiration and calcium 
homeostasis are impaired [17–19]. More recently, it was determined that mitochondrial outer membrane 
permeabilization (MOMP) mediated mitochondrial dysfunction in rodent neonatal HI models [20].  
In response to HI, the Bcl-2 family member Bax is activated and translocates to the mitochondria where 
it complexes and forms a pore with Bak allowing passage of cytochrome c and apoptosis inducing factor 
(AIF) into the cytosol. Once released AIF and cytochrome c initiate a cascade resulting in activation of 
caspases, degradation of DNA and ultimately cell death [21]. As such, genetic and pharmacological 
inhibition of Bax is protective from HI in immature brain [20,22,23]. In addition to Bax-mediated 
MOMP, mitochondrial ultrastructure is also altered in response to neonatal HI insult [10] and a wide 
range of mitochondrial morphologies are observed [13]. We therefore hypothesize that such environmental 
stress may alter mitochondrial dynamics, particularly in the proteins which regulate fission and fusion. 
Optic Atrophy 1 (OPA1), a dynamin-related guanosine triphosphatase protein, plays a pivotal role in 
conducting inner-membrane mitochondrial fusion and therefore regulates both mitochondrial cristae 
junction formation and fusion of distinct mitochondria [24–26]. Here we present data analyzing the effect 
of in vitro oxygen-glucose deprivation (OGD) and in vivo HI on the processing of OPA1. 
2. Results 
2.1. OGD in C17.2 Cells Alters Mitochondrial Function and Morphology 
OGD is a widely used in vitro technique to mimic aspects of cell death observed in in vivo HI injury. 
We performed OGD on mouse primary cortical neurons and examined mitochondrial morphology and 
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membrane potential in live cells throughout the insult using JC-1 dye. Aggregates of JC-1 accumulate 
in mitochondria in which the membrane potential is maintained, exhibiting red fluorescence, whereas 
the appearance of diffuse green JC-1 monomers throughout the cell indicates dissipation of membrane 
potential. Neurons were preloaded with JC-1 before exposure to OGD. Mitochondria were clearly visible 
in the processes of control cells and generally of uniform size (Figure 1a,b, Con). However after 90 min 
OGD, we observed an increase in green monomeric JC-1 suggesting impaired membrane potential  
and altered morphology with both mitochondrial aggregates and rounded puncta (Figure 1a,b, OGD).  
Similar findings were observed in a recent study of rat cortical neurons exposed to OGD [27], where 
control mitochondria were found to be tubular and OGD-exposed mitochondria rounded or poorly 
labelled. In order to quantify these changes, we performed time-lapse imaging on isolated neurons and 
calculated the changes in mitochondrial length over time. We found a significant decrease in the average 
mitochondrial length after 30 min of OGD (Figure 1c). After 90 min OGD we returned the cultures to 
growth medium and analyzed them at subsequent time points for the effect of the insult on mitochondrial 
health. We found that 24 h post insult, citrate synthase activity was significantly reduced indicating 
impaired TCA cycle function (Figure 1d). This suggests that neurons which survive the initial insult may 
subsequently exhibit impaired mitochondrial function. 
 
 
Figure 1. Cont. 
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Figure 1. Oxygen-glucose deprivation (OGD) alters mitochondrial membrane potential, 
morphology and function in primary cortical neurons. (a) Primary mouse cortical neurons 
were loaded with JC-1 dye and Hoechst before exposure to OGD. Cells were imaged live 
before (Con) and at 15, 45 and 90 min during OGD. Both mitochondrial morphology (as 
observed in red, top row) and membrane potential (increased green signal, second row) are 
altered during exposure to OGD. Scale bar represents 100 µm; Figures are representative of 
three individual experiments: (b) Enlargement (3×) of regions defined by white boxes in (a). 
As the experiment progresses, mitochondria morphology appears to alter from tubular 
structures to round punctate or larger aggregations; (c) Primary neurons loaded with JC-1 
were imaged every minute during OGD followed by analyses of mitochondrial length.  
Data shown are an average of 360 mitochondria per time point, and mitochondria from the 
first and last time points analyzed by student’s t-test in the panel below, *** p < 0.001;  
(d) Primary neurons were subjected to 90 min of OGD followed by up to 24 h incubation in 
normal growth medium. Lysates were assayed for citrate synthase activity at time points 
shown following the insult. Data is shown ± SD, n = 4–6 independent litters, determined  
by two-way ANOVA followed by a Bonferroni post-hoc test, ** p < 0.01 for interaction  
and treatment. 
2.2. OPA1 Processing Is Altered after OGD 
As there was a distinct alteration in mitochondrial morphology in response to OGD, we examined  
the expression of key genes involved in mitochondrial fission and fusion. Primary neurons were either 
untreated or exposed to OGD and RNA extracted at 0, 6 and 24 h post insult. Expression of fission genes 
(Drp-1, Fis-1) and fusion genes (Mitofusin 1, Mitofusin 2 and OPA1) after OGD were compared with 
expression in control untreated neurons. We found that there was a small but significant decrease in the 
expression of OPA1 mRNA comparing treatment groups (Figure 2a, a = 0.0296, two-way ANOVA for 
treatment). To further analyze changes in OGD-mediated OPA1 expression, we generated whole cell lysates 
from control and OGD-treated neurons and determined OPA1 protein expression by western blot at 0, 6 
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and 24 h post insult. There was a small decrease in the expression of OPA1 apparent at the 6 h timepoint 
(Figure 2b). Interestingly, OGD appeared to induce the generation of a smaller band and alter the 
distribution of remaining OPA1 immunoreactivity. There was a proportional shift towards expression  
of smaller OPA1 moieties most pronounced at 6 h after OGD, compared with control OPA1 expression. 
(Figure 2b, arrowheads). 
(a) 
Figure 2. Cont. 
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(b) 
Figure 2. OPA1 processing is altered after OGD (a) mRNA generated from control (white 
bars) and OGD-treated (grey bars) primary neurons was analyzed by qRT-PCR for changes 
in expression of fission (Drp1, Fis1) and fusion genes (Mitofusin 1 and 2, OPA1). There was 
a small but significant decrease in OPA1 expression in response to OGD exposure  
(a = 0.0296). Mean data shown ± SD (n = 4–5 independent litters), significance determined 
by two way ANOVA; (b) Protein lysates were generated from primary neurons either 
immediately after 90 min OGD (0 h) or following 6 or 24 h recovery. Proteins were resolved 
by SDS-PAGE and OPA1 analyzed by western blot. Equal protein loading was determined 
by GAPDH expression. Size distribution of the OPA1 immunoreactivity is expressed as  
a proportion of total OPA1 (arrowheads). There was a significant increase in the  
expression of the OPA1 lower band at 0 and 6 h, significance determined by two-way 
ANOVA for treatment and band. If there was a significant interaction, a Bonferroni post-hoc 
was performed. Data are mean ± SD (n = 3 independent litters), * p < 0.05, *** p < 0.001, 
**** p < 0.0001. 
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2.3. OGD Reduces Yme1L Protein Expression in Primary Neurons 
Alternative splicing of OPA1 generates eight isoforms which depending on variant, will contain S1 
and S2 cleavage sites, or an S1 site alone [28]. Previous studies have demonstrated that cleavage at  
S2 by the intermembrane space AAA-protease Yme1L produces a balance of long and short OPA1 products, 
optimal for OPA1 function [24,29]. When mitochondrial membrane potential is lost, Oma1,  
a zinc-metalloprotease which resides on the inner membrane, cleaves OPA1 at the S1 site [30,31].  
We therefore examined the expression of Yme1L and Oma1 in primary neurons exposed to OGD. 
Although gene expression of Yme1L was not altered significantly in response to OGD (Yme1L  
p = 0.0506; Figure 3a), there was a discernible decrease in Yme1L protein expression at the end of OGD 
(Figure 3b). Conversely, no changes were apparent for either the gene (Figure 3c) or protein expression 
(Figure 3d) of Oma1. 
 
Figure 3. Cont. 
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Figure 3. Yme1L protein expression is reduced after OGD (a) mRNA generated from 
control and OGD-treated primary neurons was analyzed by qRT-PCR for changes in 
expression of Yme1L. Data shown ± SD, n = 3–4 independent litters; (b) Protein lysates 
were generated from primary neurons immediately following OGD and analyzed by western 
blot for expression of Yme1L. Equal protein loading was determined by GAPDH expression 
which was used for the quantification (right hand panel). Figure is representative of three 
individual litters, * p < 0.05 determined by students t-test; (c) Oma1 gene expression or (d) 
Oma1 protein expression was determined as above with GAPDH for equal loading.  
Data was analyzed as above. Figure is representative of three individual litters. 
2.4. Alterations in OPA1 Processing Are Apparent in Vivo after HI 
Finally we determined if these effects occurred in vivo in an animal model of term HI. We used the 
well-characterized Vannucci HI model in mouse P9 pups, which recapitulates aspects of delayed cell 
death in human perinatal HI [32,33]. Following unilateral carotid artery ligation, pups are exposed to 
hypoxia for 75 min before returning to normoxia. This allows both hypoxic (contralateral hemisphere) 
and hypoxic-ischemic (ipsilateral hemisphere) brain tissue to be sampled from the same animal.  
Brain tissue was harvested at 0, 24 and 48 h post injury, mitochondrial fractions isolated and OPA1, 
Yme1L and Oma1 analyzed by western blot (Figure 4a). We found that the bias towards cleaved OPA1 
was clearly visible in the hypoxic-ischemic samples from the earliest time point, with a significant 
decrease of upper band intensity correlating with a significant increase in middle band intensity  
(Figure 4a, 0 h). Furthermore an additional band of a lower molecular weight was clearly visible  
in the 24 (Figure 4b) and 48 h (Figure 4c) HI samples. We quantified the upper, middle and lower 
molecular weight OPA1 bands as a proportion of total OPA1 and observed a significant decrease in the 
upper band after HI but not hypoxia alone, which was accompanied by a significant increase in the 
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expression of the lower form (Figure 4b). In addition to changes in OPA1, there was a distinct trend 
towards a decrease in Yme1L expression at 0 (Figure 4a) and 24 h (Figure 4b) which appeared to be 
resolved by 48 h. Throughout the time course of the experiment, Oma1 expression did not appear to vary 
(Figure 4a–c). In summary, our data suggest that OGD in vitro and HI injury in vivo result in cleavage 
of OPA1 to lower molecular weight forms. This observation correlates with an OGD- or HI-mediated 
decrease in Yme1L expression. 
 
 
Figure 4. Cont. 
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Figure 4. Aberrant processing of OPA1 in vivo. Mitochondrial fractions were generated 
from hypoxic-ischemic (HI), hypoxia alone or sham control mice. Proteins were resolved by 
SDS-PAGE and analyzed by western blot for OPA1, Yme1L and Oma1 at 0 (a), 24 (b)  
and 48 h (c) following HI. Tom20 was used as a loading control for mitochondria (bottom 
panel). Total OPA1 expression was determined by densitometry and OPA1 isoforms or 
cleavage products expressed as a proportion of that total. Arrowheads indicate alternate 
forms of OPA1. Mean data shown ± SD. OPA1 significance was determined by two-way 
ANOVA for band size and treatment followed by a Bonferroni post-hoc test * p < 0.05,  
** p < 0.01, *** p < 0.001, **** p < 0.0001. YME1L and Oma1 data were analyzed with  
a one-way ANOVA. 
3. Discussion 
Dysregulation of energy metabolism is a common feature in a number of human diseases including 
diabetes, cardiovascular and neurodegenerative disorders [34–36]. It is therefore unsurprising the 
mitochondria are center stage in the development of neonatal brain injury, due to additional high energy 
demands of the immature brain as it develops [15], and protecting mitochondrial function represents a 
valid target for future therapeutic intervention. Here we present data suggesting that the homeostasis of 
inner mitochondrial membrane proteins is disrupted in response to OGD in vitro and HI in vivo and that 
alterations in protein function are due largely to post-translational modification. 
Although we only identified small changes in OPA1 gene expression, our major finding is that OPA1 
is rapidly cleaved to shorter forms in response to hypoxia-ischemia. Shortened forms of OPA1 are 
reported to occur as a result of environmental stress, resulting in fragmented mitochondria [37,38]. 
Furthermore, actively altering the balance of long (L-OPA1) and short (S-OPA1) forms may favor 
mitochondrial fission [39], agreeing with the appearance of small punctate mitochondria apparent during 
the OGD insult in primary neurons (Figure 1). 
OPA1 cleavage occurs due to the actions of the ATP-dependent protease Yme1L and the  
ATP-independent protease Oma1 [30,31]. Yme1L cleaves OPA1 at the S2 site and subsequent products 
remain fusion-competent [24,29]. However, loss of mitochondrial membrane potential results in 
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cleavage at OPA1 S1 site by Oma1 and generation of fusion-incompetent mitochondria [31]. Our results 
(Figure 1) and those of others [27,40] suggest that exposure of primary neurons to OGD induces  
a decrease in mitochondrial membrane potential coupled with changes in mitochondrial morphology 
(Figure 1, Con vs. OGD). 
Concomitantly, post insult, we observed a decrease in Yme1L protein expression in vitro (Figure 3) 
and in vivo (Figure 4). It is well established that in animal models of HI and in vitro, the insult induces 
a rapid depletion of cellular ATP [8,33,41]. Yme1L activity is ATP-dependent and more recently, its 
expression was found to be reduced following oxidative stress [42]. These authors also identified Oma1 
as an ATP-independent protease which regulated Yme1L expression; resistance to Oma1-mediated 
Yme1L degradation was conferred by ATP binding. Both our in vitro and our in vivo results are in  
line with these findings suggesting that loss of Yme1L may sensitize cells to oxidative stress through 
dysfunctional mitochondrial dynamics [43]. However, further work is required to determine whether 
disrupting the balance of Yme1L and Oma1 is critical in neonatal hypoxic-ischemic brain injury. 
In the development of neonatal brain injury in response to HI insult, we and others have documented 
the induction of apoptosis resulting in cytochrome c release from permeabilized mitochondria [13,44–46]. 
However, the majority of cytochrome c is held within the cristae, relying on cristae reconfiguration  
to allow it access to move into the intermembrane space once apoptosis is induced. In addition to its  
role in fusion, OPA1 controls the integrity of the cristae [25] and inhibition of OPA1 leads to cristae 
disorganization [26]. Our data suggest the possibility that OPA1 processing may be an early but key step 
in the propagation of neuronal cell death induced by neonatal hypoxic-ischemic injury. Interestingly, 
during revision of our manuscript, Sanderson and colleagues identified release of cytochrome c and 
appearance of degraded OPA1 in the cytosol in response to OGD/reperfusion in primary neurons [47] 
providing further evidence for our hypothesis. Our future studies will therefore center on the roles of 
Yme1L and Oma1 in the regulation of OPA1 in order to highlight whether prevention of such cleavage 
is neuroprotective in neonatal hypoxic-ischemic injury. 
4. Experimental Section 
4.1. Research Ethics Statement 
All animal use was in accordance with local rules (King’s College London, Animal Welfare and 
Ethical Review Board, London, UK) and with the regulations and guidance issued under the Animals 
(Scientific Procedures) Act (1986) covered by Home Office personal and project licenses. 
4.2. Primary Cortical Neuron Preparation 
C57/Bl6 pregnant mice (Charles Rivers, Margate, UK) at embryonic day 13.5–15.5 were killed  
by schedule 1 methods. Embryonic cerebral cortices were dissected and tissue from the same litter  
pooled. Primary cortical neurons were prepared as described previously [48], plated at a density of  
2 × 106 cells/6 cm plate and maintained in neurobasal medium (Life Technologies, Paisley, UK) 
containing B27® (Life Technologies), L-Glutamine (Sigma, Gillingham, UK) and Streptomycin/ 
AmphotericinB (Life Technologies,). Cultures were maintained at 37 °C, 5% CO2. 
  
Int. J. Mol. Sci. 2015, 16 22520 
 
 
4.3. Neonatal Hypoxia-Ischemia 
C57/Bl6 mice (Charles River) at postnatal day 9 (P9) were subjected to unilateral hypoxia-ischemia, 
essentially according to the Rice–Vannucci model that results in a focal ischemic injury allowing for 
comparison between an HI (ipsilateral) and hypoxia alone (contralateral) hemisphere [32,33]. Briefly, 
mice were anesthetized with isoflurane (4.5% for induction and 2% for maintenance) in a mixture of 
nitrous oxide and oxygen (1:1), with the duration of anesthesia being <5 min per pup. The left common 
carotid artery was isolated and ligated. Pups recovered for 1–2 h in the parent cage. Litters were  
placed in a chamber with a humidified hypoxic gas mixture (10% oxygen in nitrogen, 36 °C) for 75 min.  
Sham control mice were not subjected to surgery or hypoxic chamber. After hypoxic exposure, pups 
were returned to their biological dams until the conclusion of the experiment. Both females and males 
pups were used and treatment groups contained pups from at least 3 independent litters. 
4.4. Oxygen-Glucose Deprivation (OGD) of Primary Neurons 
Primary neurons were cultured for a minimum of 6 days (DIV6) prior to treatment then loaded with 
JC-1 (5 µM; Life Technologies) and Hoechst (10 µg/mL; Sigma) for 30 min, 37 °C, 5% CO2. Growth 
medium was replaced with de-gassed, glucose-free, Neurobasal-A medium (Life Technologies) and 
culture plates mounted on the EVOS/Chamlide microscope (Life Technologies) where they were 
maintained at 37 °C in a 95% N2/5% CO2 environment for the duration of the OGD. Following OGD, 
medium was replaced with standard Neurobasal medium (containing additions described above)  
and cultures returned to 5% CO2 incubation. For control plates, medium was replaced with standard 
Neurobasal media at the start of the OGD plates and replaced again with media after 90 min. Cells were 
collected at 0, 6 or 24 h following treatment. 
4.5. MTT Assay 
Primary cortical neurons were assayed for mitochondrial reductase activity using the MTT  
(3-(4,5-Dimethylthiazol-2-yl-)-2,5-diphenyl-2H-tetrazolium bromide; Sigma) assay as described 
previously [49]. 
4.6. Citrate Synthase Assay 
Primary neurons were lysed in CelLytic MT Cell Lysis Reagent (Sigma), protein concentration 
determined by BCA assay (Thermo Scientific, Loughborough, UK) and were assayed for enzymatic 
activity using Citrate Synthase Assay Kit (Sigma) according to manufacturer’s instructions.  
Eight micrograms of total protein was used per reaction on a 96-well plate and independent samples 
were measured in duplicate. Absorbance was read at 412 nm on a SPECTROstar Nano plate reader using 
MARS analysis software (BMG Labtech, Aylesbury, UK). Baseline absorbance was measured every  
30 s for 5 min, and following addition of oxaloacetic acid, total activity was measured every 10 min for 
60 min. 
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4.7. qRT-PCR 
RNA was harvested using the Direct-zol RNA MiniPrep kit (Zymo Research, through Cambridge 
Biosciences, Cambridge UK) as per manufacturer’s instructions. Total RNA (100 ng) was analysed 
using Taqman gene expression assays and RNA-to-CT kit (Life Technologies) on a StepOneplus Cycler 
(Life Technologies). Data were normalized to the expression of GAPDH and to controls for each time 
point using the 2−ΔΔCt method [50]. The following primer pairs were used: GAPDH (Mm99999915), 
DRP1 (Dmn1; Mm01342903), Fis1 (Mm00481580), Mitofusin1 (Mm00612599), Mitofusin2 
(Mm00500120), OPA1 (Mm01349707), Oma1 (Mm01260328) and Yme1L (Mm00496843) from  
Life Technologies. 
4.8. Subcellular Fractionation 
For preparation of mitochondrial fractions, mice were sacrificed at 0, 24 and 48 h post HI and brains 
rapidly dissected into ice-cold subcellular fractionation buffer (250 mM sucrose, 20 mM HEPES pH 7.4, 
10 mM KCL, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1× protease inhibitor cocktail). 
Samples were homogenized in a 2 mL dounce homogenizer on ice, passed through a 27 G needle and 
incubated on ice for 20 min. The suspension was centrifuged (720× g, 5 min) to remove the nuclear 
fraction and any unbroken cells. The resulting supernatant was centrifuged (15,000× g, 15 min) to obtain 
a mitochondrial pellet and a cytosolic supernatant. 
4.9. Western Blot 
For protein analysis primary neurons were lysed in HEPES buffer A (50 mM HEPES (pH 7.5),  
50 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM EDTA, +1× protease inhibitors (Sigma)) 
containing 1% (v/v) Triton X-100 (Sigma). Protein from cell lysates (50 µg) and mitochondrial fractions 
from brain lysates (30 µg) were resolved on 4%–12% gel (w/v) NuPAGE BisTris gels in MOPs buffer 
(ThermoFisher Scientific, Hemel Hempstead, UK) and transferred to polyvinylidene fluoride membrane 
(PVDF, Millipore, Beeston, UK) in NuPAGE transfer buffer (Life Technologies). Membranes were 
blocked in 5% skim-milk in Tris-buffered saline with 0.1% Tween 20 (TBS-T) and incubated overnight 
with the following antibodies: anti-mouse OPA1 (1:1000, Cat# 612606, BD Biosciences, Oxford, UK), 
anti-rabbit YME1 (1:1000, Cat# 11510-1-AP, ProteinTech, Manchester, UK), anti-rabbit OMA1 (for 
primary neurons; 1:1000, Cat# NBP1-56970, Novusbio, UK and for mitochondrial fractions from brain 
lysates; 1:750, Cat# 17116-1-AP, ProteinTech), anti-mouse GAPDH (1:2000, Cat# G8795 Sigma) and 
for mitochondrial fractions Tom20 (1:750, Cat# sc-11415, Santa Cruz Biotechnology, Wembley, UK). 
Secondary antibodies: Li-cor IRDye Goat anti-rabbit 800 or Goat anti-mouse 680 secondary antibodies 
were used at 1:10,000 and incubated for 2 h at room temperature. Membranes were imaged on a Li-Cor 
Odyssey Infrared Imaging System (Li-Cor Imaging Biotechnology UK Ltd., Cambridge, UK) using the 
manufacturer’s Image Studio software for band quantification. 
4.10. Data Analysis 
Data are expressed as mean ± SD. All primary neuronal culture experiments were performed on  
3–6 independent litters as stated in the figure legends. Mitochondrial length was analyzed using Squassh 
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(segmentation and quantification of subcellular shapes) software, part of the Mosaic toolkit in  
Image J [51]. All statistical analyses were performed using GraphPad Prism 6 Software (GraphPad 
Software, San Diego, CA, USA). All data were assessed for normality. Data was assessed either by  
a Student’s t-test or for multiple conditions, with a two-way ANOVA. If significant, a Bonferroni  
post-hoc analysis was conducted. Analyses used are detailed in table and figure captions. * p < 0.05,  
** p < 0.01, *** p < 0.001, **** p < 0.0001. 
5. Conclusions 
We have determined that in primary neurons, mitochondrial membrane potential, morphology and 
function are impaired in response to OGD. Furthermore, we present the first data suggesting that in  
a mouse model of neonatal HI, the expression of mitochondrial shaping proteins, such as OPA1 and 
Yme1L, are altered; in vitro and in vivo, OPA1 is cleaved to shorter forms and Yme1L expression is 
reduced. Further studies are required to determine the molecular pathways regulating these events. 
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